Advertisement

Advanced-Stage Breast Cancer Radiotherapy

  • Kamuran Arslan Ibis
  • Seden Kucucuk
Chapter

Abstract

Radiotherapy is a part of breast cancer treatment in every stage, from non-invasive to early, locally advanced, recurrent and metastatic disease. In patients who previously received neoadjuvant chemotherapy, radiotherapy fields are determined based on the pre-chemotherapy disease stage. Radiotherapy is also an effective treatment option in patients with locally recurrent disease, but doses >100 Gy are associated with increased toxicities. Finally, radiotherapy is administered not only for the ablation of metastases in oligometastatic patients but also for the palliation of symptoms in patients with widespread metastatic disease.

Keywords

Neoadjuvant chemotherapy Preoperative chemotherapy Metastases 

References

  1. 1.
    Mamounas EP, Anderson SJ, Dignam JJ, Bear HD, Julian TB, Geyer CE Jr, et al. Predictors of locoregional recurrence after neoadjuvant chemotherapy: results from combined analysis of National Surgical Adjuvant Breast and Bowel Project B-18 and B-27. J Clin Oncol. 2012;30(32):3960–6.CrossRefGoogle Scholar
  2. 2.
    De Felice F, Osti MF, De Sanctis V, Musio D, Tombolini V. Critical decision-making in radiotherapy for early stage breast cancer in a neo-adjuvant treatment era. Expert Rev Anticancer Ther. 2017;17(5):481–5.CrossRefGoogle Scholar
  3. 3.
    Garg AK, Buchholz TA. Influence of neoadjuvant chemotherapy on radiotherapy for breast cancer. Ann Surg Oncol. 2015;22(5):1434–40.CrossRefGoogle Scholar
  4. 4.
    National Cancer Institute Trial. Standard or comprehensive radiation therapy in treating patients with early-stage breast cancer previously treated with chemotherapy and surgery. www.clinicaltrials.gov.
  5. 5.
    Kao J, Conzen SD, Jaskowiak NT, Song DH, Recant W, Singh R, et al. Concomitant radiation therapy and paclitaxel for unresectable locally advanced breast cancer: results from two consecutive phase I/II trials. Int J Radiat Oncol Biol Phys. 2005;61(4):1045–53.CrossRefGoogle Scholar
  6. 6.
    Karasawa K, Saito M, Hirowatari H, Izawa H, Furuya T, Ozawa S, et al. The role of chemoradiotherapy in patients with unresectable T4 breast tumors. Breast Cancer. 2013;20(3):254–61.CrossRefGoogle Scholar
  7. 7.
    Shaughnessy JN, Meena RA, Dunlap NE, Jain D, Riley EC, Quillo AR, et al. Efficacy of concurrent chemoradiotherapy for patients with locally recurrent or advanced inoperable breast cancer. Clin Breast Cancer. 2015;15(2):135–42.CrossRefGoogle Scholar
  8. 8.
    Fisher B, Jeong JH, Anderson S, Bryant J, Fisher ER, Wolmark N. Twenty-five-year follow-up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation. N Engl J Med. 2002;347(8):567–75.CrossRefGoogle Scholar
  9. 9.
    Ragaz J, Olivotto IA, Spinelli JJ, Philips N, Jackson SM, Wilson KS, et al. Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trial. J Natl Cancer Inst. 2005;97(2):116–26.CrossRefGoogle Scholar
  10. 10.
    Faneyte IF, Rutgers EJ, Zoetmulder FA. Chest wall resection in the treatment of locally recurrent breast carcinoma: indications and outcome for 44 patients. Cancer. 1997;80(5):886–91.CrossRefGoogle Scholar
  11. 11.
    Schwaibold F, Fowble BL, Solin LJ, Schultz DJ, Goodman RL. The results of radiation therapy for isolated local regional recurrence after mastectomy. Int J Radiat Oncol Biol Phys. 1991;21(2):299–310.CrossRefGoogle Scholar
  12. 12.
    Skinner HD, Strom EA, Motwani SB, Woodward WA, Green MC, Babiera G, et al. Radiation dose escalation for loco-regional recurrence of breast cancer after mastectomy. Radiat Oncol. 2013;8:13.CrossRefGoogle Scholar
  13. 13.
    Halverson KJ, Perez CA, Kuske RR, Garcia DM, Simpson JR, Fineberg B. Locoregional recurrence of breast cancer: a retrospective comparison of irradiation alone versus irradiation and systemic therapy. Am J Clin Oncol. 1992;15(2):93–101.CrossRefGoogle Scholar
  14. 14.
    Delanian S, Housset M, Brunel P, Rozec C, Maulard C, Huart J, et al. Iridium 192 plesiocurietherapy using silicone elastomer plates for extensive locally recurrent breast cancer following chest wall irradiation. Int J Radiat Oncol Biol Phys. 1992;22(5):1099–104.CrossRefGoogle Scholar
  15. 15.
    Harms W, Krepien R, Hensley FW, Berns C, Wannenmacher M, Fritz P. Results of chest wall reirradiation using pulsed-dose-rate (PDR) brachytherapy molds for breast cancer local recurrences. Int J Radiat Oncol Biol Phys. 2001;49(1):205–10.CrossRefGoogle Scholar
  16. 16.
    Chadha M, Feldman S, Boolbol S, Wang L, Harrison LB. The feasibility of a second lumpectomy and breast brachytherapy for localized cancer in a breast previously treated with lumpectomy and radiation therapy for breast cancer. Brachytherapy. 2008;7(1):22–8.CrossRefGoogle Scholar
  17. 17.
    Guix B, Lejarcegui JA, Tello JI, Zanon G, Henriquez I, Finestres F, et al. Exeresis and brachytherapy as salvage treatment for local recurrence after conservative treatment for breast cancer: results of a ten-year pilot study. Int J Radiat Oncol Biol Phys. 2010;78(3):804–10.CrossRefGoogle Scholar
  18. 18.
    Deutsch M. Repeat high-dose external beam irradiation for in-breast tumor recurrence after previous lumpectomy and whole breast irradiation. Int J Radiat Oncol Biol Phys. 2002;53(3):687–91.CrossRefGoogle Scholar
  19. 19.
    Wadasadawala T, Vadgaonkar R, Bajpai J. Management of isolated locoregional recurrences in breast cancer: a review of local and systemic modalities. Clin Breast Cancer. 2017;17(7):493–502.CrossRefGoogle Scholar
  20. 20.
    Chadha M, Mehta P, Feldman S, Boolbol SK, Harrison LB. Intraoperative high-dose-rate brachytherapy—a novel technique in the surgical management of axillary recurrence. Breast J. 2009;15(2):140–5.CrossRefGoogle Scholar
  21. 21.
    Hannoun-Levi JM, Houvenaeghel G, Ellis S, Teissier E, Alzieu C, Lallement M, et al. Partial breast irradiation as second conservative treatment for local breast cancer recurrence. Int J Radiat Oncol Biol Phys. 2004;60(5):1385–92.CrossRefGoogle Scholar
  22. 22.
    Siglin J, Champ CE, Vakhnenko Y, Anne PR, Simone NL. Radiation therapy for locally recurrent breast cancer. Int J Breast Cancer. 2012;2012:571946.CrossRefGoogle Scholar
  23. 23.
    Vernon CC, Hand JW, Field SB, Machin D, Whaley JB, van der Zee J, et al. Radiotherapy with or without hyperthermia in the treatment of superficial localized breast cancer: results from five randomized controlled trials. International Collaborative Hyperthermia Group. Int J Radiat Oncol Biol Phys. 1996;35(4):731–44.CrossRefGoogle Scholar
  24. 24.
    Jones EL, Oleson JR, Prosnitz LR, Samulski TV, Vujaskovic Z, Yu D, et al. Randomized trial of hyperthermia and radiation for superficial tumors. J Clin Oncol. 2005;23(13):3079–85.CrossRefGoogle Scholar
  25. 25.
    Datta NR, Puric E, Klingbiel D, Gömez S, Bodis S. Hyperthermia and radiation therapy in locoregional recurrent breast cancers: a systematic review and meta-analysis. Int J Radiat Oncol Biol Phys. 2016;94(5):1073–87.CrossRefGoogle Scholar
  26. 26.
    Zagar TM, Higgins KA, Miles EF, Vujaskovic Z, Dewhirst MW, Clough RW, et al. Durable palliation of breast cancer chest wall recurrence with radiation therapy, hyperthermia, and chemotherapy. Radiother Oncol. 2010;97(3):535–40.CrossRefGoogle Scholar
  27. 27.
    Janssen S, Rades D. Primary breast cancer with synchronous metastatic disease - indications for local radiotherapy to the breast and chest wall. Anticancer Res. 2015;35(11):5807–12.PubMedGoogle Scholar
  28. 28.
    Albain KS, Nag SM, Calderillo-Ruiz G, Jordaan JP, Llombart AC, Pluzanska A, et al. Gemcitabine plus paclitaxel versus paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment. J Clin Oncol. 2008;26(24):3950–7.CrossRefGoogle Scholar
  29. 29.
    Bergh J, Bondarenko IM, Lichinitser MR, Liljegren A, Greil R, Voytko NL, et al. First-line treatment of advanced breast cancer with sunitinib in combination with docetaxel versus docetaxel alone: results of a prospective, randomized phase III study. J Clin Oncol. 2012;30(9):921–9.CrossRefGoogle Scholar
  30. 30.
    Tawfik H, Rostom Y, Elghazaly H. All-oral combination of vinorelbine and capecitabine as first-line treatment in HER2/Neu-negative metastatic breast cancer. Cancer Chemother Pharmacol. 2013;71(4):913–9.CrossRefGoogle Scholar
  31. 31.
    Hurvitz SA, Dirix L, Kocsis J, Bianchi GV, Lu J, Vinholes J, et al. Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol. 2013;31(9):1157–63.CrossRefGoogle Scholar
  32. 32.
    Gianni L, Romieu GH, Lichinitser M, Serrano SV, Mansutti M, Pivot X, et al. AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer. J Clin Oncol. 2013;31(14):1719–25.CrossRefGoogle Scholar
  33. 33.
    Sledge GW, Neuberg D, Bernardo P, Ingle JN, Martino S, Rowinsky EK, et al. Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193). J Clin Oncol. 2003;21(4):588–92.CrossRefGoogle Scholar
  34. 34.
    Dorn PL, Meriwether A, LeMieux M, Weichsel baum RR, Chmura SJ, Hasan Y. Patterns of distant failure and progression in breast cancer: implications for the treatment of oligometastatic disease. Int J Radiat Oncol Biol Phys. 2011;81:S643.CrossRefGoogle Scholar
  35. 35.
    Milano MT, Zhang H, Metcalfe SK, Muhs AG, Okunieff P. Oligometastatic breast cancer treated with curative-intent stereotactic body radiation therapy. Breast Cancer Res Treat. 2009;115(3):601–8.CrossRefGoogle Scholar
  36. 36.
    Formenti SC, Friedman K, Chao K, Adams S, Fenton-Kerimian M, Donach ME, et al. Abscopal response in irradiated patients: results of a proof of priniciple trial. Int J Radiat Oncol Biol Phys. 2008;72:6–7.CrossRefGoogle Scholar
  37. 37.
    Postow MA, Callahan MK, Barker CA, Yamada Y, Yuan J, Kitano S, et al. Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med. 2012;366(10):925–31.CrossRefGoogle Scholar
  38. 38.
    Dellas K. Does radiotherapy have curative potential in metastatic patients? The concept of local therapy in oligometastatic breast cancer. Breast Care. 2011;6(5):363–8.CrossRefGoogle Scholar
  39. 39.
    Tree AC, Khoo VS, Eeles RA, Ahmed M, Dearnaley DP, Hawkins MA, et al. Stereotactic body radiotherapy for oligometastases. Lancet Oncol. 2013;14(1):e28–37.CrossRefGoogle Scholar
  40. 40.
    Corbin KS, Hellman S, Weichselbaum RR. Extracranial oligometastases: a subset of metastases curable with stereotactic radiotherapy. J Clin Oncol. 2013;31(11):1384–90.CrossRefGoogle Scholar
  41. 41.
    Milano MT, Katz AW, Zhang H, Okunieff P. Oligometastases treated with stereotactic body radiotherapy: long-term follow-up of prospective study. Int J Radiat Oncol Biol Phys. 2012;83(3):878–86.CrossRefGoogle Scholar
  42. 42.
    Dawood S, Gonzalez-Angulo AM. Progress in the biological understanding and management of breast cancer-associated central nervous system metastases. Oncologist. 2013;18(6):675–84.CrossRefGoogle Scholar
  43. 43.
    Karaman Ş, Kücücük S. Neurological metastases. In: Aydiner A, İgci A, Soran A, editors. Breast disease. Cham: Springer; 2016.Google Scholar
  44. 44.
    Cardoso F, Costa A, Norton L, Cameron D, Cufer T, Fallowfield L, et al. 1st International consensus guidelines for advanced breast cancer (ABC 1). Breast. 2012;21(3):242–52.CrossRefGoogle Scholar
  45. 45.
    Dyer MA, Kelly PJ, Chen YH, Pinnell NE, Claus EB, Lee EQ, et al. Importance of extracranial disease status and tumor subtype for patients undergoing radiosurgery for breast cancer brain metastases. Int J Radiat Oncol Biol Phys. 2012;83(4):e479–86.CrossRefGoogle Scholar
  46. 46.
    Anders CK, Deal AM, Miller CR, Khorram C, Meng H, Burrows E, et al. The prognostic contribution of clinical breast cancer subtype, age, and race among patients with breast cancer brain metastases. Cancer. 2011;117(8):1602–11.CrossRefGoogle Scholar
  47. 47.
    Linskey ME, Andrews DW, Asher AL, Burri SH, Kondziolka D, Robinson PD, et al. The role of stereotactic radiosurgery in the management of patients with newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. J Neuro-Oncol. 2010;96(1):45–68.CrossRefGoogle Scholar
  48. 48.
    Gaspar LE, Mehta MP, Patchell RA, Burri SH, Robinson PD, Morris RE, et al. The role of whole brain radiation therapy in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. J Neuro-Oncol. 2010;96(1):17–32.CrossRefGoogle Scholar
  49. 49.
    Kalkanis SN, Kondziolka D, Gaspar LE, Burri SH, Asher AL, et al. The role of surgical resection in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. J Neuro-Oncol. 2010;96(1):33–43.CrossRefGoogle Scholar
  50. 50.
    Patil CG, Pricola K, Sarmiento JM, Garg SK, Bryant A, Black KL. Whole brain radiation therapy (WBRT) alone versus WBRT and radiosurgery for the treatment of brain metastases. Cochrane Database Syst Rev. 2012;9:CD006121.Google Scholar
  51. 51.
    Andrews DW, Scott CB, Sperduto PW, Flanders AE, Gaspar LE, Schell MC, et al. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet. 2004;363(9422):1665–72.CrossRefGoogle Scholar
  52. 52.
    Combs SE, Schulz-Ertner D, Thilmann C, Edler L, Debus J. Treatment of cerebral metastases from breast cancer with stereotactic radiosurgery. Strahlenther Onkol. 2004;180(9):590–6.CrossRefGoogle Scholar
  53. 53.
    Mahajan A, Ahmed S, McAleer MF, Weinberg JS, Li J, Brown P, et al. Post-operative stereotactic radiosurgery versus observation for completely resected brain metastases: a single-centre, randomised, controlled, phase 3 trial. Lancet Oncol. 2017;18(8):1040–8.CrossRefGoogle Scholar
  54. 54.
    Cardoso F, Costa A, Norton L, Senkus E, Aapro M, Andre F, et al. ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2) dagger. Ann Oncol. 2014;25(10):1871–88.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Kamuran Arslan Ibis
    • 1
  • Seden Kucucuk
    • 1
  1. 1.Istanbul Medical Faculty, Department of Radiation Oncology, Istanbul University, Institute of OncologyIstanbulTurkey

Personalised recommendations